paclitaxel mylan
viatris limited - paclitaxel 6 mg/ml - concentrate for injection - 6 mg/ml - active: paclitaxel 6 mg/ml excipient: citric acid ethanol nitrogen polyoxyl 35 castor oil - primary treatment of ovarian cancer in combination with other chemotherapeutic agents treatment of metastatic carcinoma of the ovary after failure of standard therapy
irinotecan actavis 100
teva pharma (new zealand) limited - irinotecan hydrochloride trihydrate 100mg; irinotecan hydrochloride trihydrate 100mg - concentrate for injection - 100 mg - active: irinotecan hydrochloride trihydrate 100mg excipient: lactic acid sodium hydroxide sorbitol water for injection active: irinotecan hydrochloride trihydrate 100mg excipient: hydrochloric acid lactic acid sodium hydroxide sorbitol water for injection - irinotecan actavis is indicated as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan actavis is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.
irinotecan actavis 40
teva pharma (new zealand) limited - irinotecan hydrochloride trihydrate 40mg; irinotecan hydrochloride trihydrate 40mg - concentrate for injection - 40 mg - active: irinotecan hydrochloride trihydrate 40mg excipient: lactic acid sodium hydroxide sorbitol water for injection active: irinotecan hydrochloride trihydrate 40mg excipient: hydrochloric acid lactic acid sodium hydroxide sorbitol water for injection - irinotecan actavis is indicated as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan actavis is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.
next choice
teva pharma (new zealand) limited - levonorgestrel 0.75mg - tablet - 0.75 mg - active: levonorgestrel 0.75mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch povidone sunset yellow fcf - next choice is an oral emergency contraceptive indicated for use within 72 hours of unprotected intercourse. it should be used only as an emergency measure. women who present for repeated courses of emergency contraception should be advised to consider long-term methods of contraception.
next choice
teva pharma (new zealand) limited - levonorgestrel 0.75mg - tablet - 750 mcg - active: levonorgestrel 0.75mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch povidone sunset yellow fcf - next choice is an oral emergency contraceptive indicated for use within 72 hours of unprotected intercourse. it should be used only as an emergency measure. women who present for repeated courses of emergency contraception should be advised to consider long-term methods of contraception.
oncotaxel 140
actavis new zealand limited - docetaxel 140mg - concentrate for injection - 140 mg - active: docetaxel 140mg excipient: citric acid ethanol nitrogen polysorbate 80 povidone
oncotaxel 20
actavis new zealand limited - docetaxel 20mg - concentrate for injection - 20 mg - active: docetaxel 20mg excipient: citric acid ethanol nitrogen polysorbate 80 povidone
oncotaxel 80
actavis new zealand limited - docetaxel 80mg - concentrate for injection - 80 mg - active: docetaxel 80mg excipient: citric acid ethanol nitrogen polysorbate 80 povidone
paclitaxel
rex medical ltd - paclitaxel 6 mg/ml - solution for injection - 6 mg/ml - active: paclitaxel 6 mg/ml excipient: castor oil citric acid ethanol - paclitaxel injection is indicated for the primary treatment of ovarian cancer in combination with other chemotherapeutic agents.
paclitox
viatris limited - paclitaxel 6 mg/ml - concentrate for injection - 6 mg/ml - active: paclitaxel 6 mg/ml excipient: citric acid ethanol nitrogen polyoxyl 35 castor oil - primary treatment of ovarian cancer in combination with other chemotherapeutic agents treatment of metastatic carcinoma of the ovary after failure of standard therapy